Factor IX activity measurement of recombinant FIX Fc fusion protein eftrenonacog alfa with one-stage clotting and chromogenic substrate assay

被引：0
|
作者：
Prudkova, Marie [1 ,2 ,3 ,4 ]
Chytra, Dagmar [1 ,4 ]
Smejkal, Petr [1 ,4 ]
Zavrelova, Jirina [1 ,4 ]
Kovarikova, Jana [1 ,4 ]
Penka, Miroslav [1 ,2 ,3 ]
Bulikova, Alena [1 ,2 ,3 ]
机构：
[1] Univ Hosp Brno, Dept Clin Hematol, Brno, Czech Republic
[2] Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic
[3] Masaryk Univ Brno, Fac Med, Brno, Czech Republic
[4] Masaryk Univ Brno, Dept Lab Methods, Fac Med, Brno, Czech Republic
来源：
HAEMOPHILIA | 2024年 / 30卷
关键词：
chromogenic substrate assay; one-stage clotting assay; recombinant factor IX Fc fusion protein;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PP-074 (16
引用
收藏
页码：87 / 87
页数：1
相关论文
共 50 条
  • [41] MEASURING OF COAGULANT ACTIVITY IN ACTIVATED FACTOR-VII CONCENTRATES USING A ONE-STAGE CLOTTING ASSAY CALIBRATED WITH RECOMBINANT ACTIVATED FACTOR-VII
    JACOBSEN, JK
    NIELSEN, GG
    NIELSEN, FE
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 866 - 866
  • [42] Superiority of the chromogenic assay specific for activated factor IX over the non-activated partial thromboplastine time (NAPTT) clotting assay in detecting FIXa in recombinant FIX preparations
    Dockal, M.
    Boehm, E.
    Pilz, J.
    Schrenk, G.
    Varadi, K.
    Scheiflinger, F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 540 - 541
  • [43] The effect of different APTT reagents on the potencies of plasma-derived and recombinant factor IX concentrates in one-stage clotting assays
    Wilmot, H., V
    Hogwood, J.
    Gray, E.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 829 - 829
  • [44] Real-world assay variability between laboratories in monitoring of recombinant factor IX Fc fusion protein activity in plasma samples
    Sommer, Jurg M.
    Sadeghi-Khomami, Ali
    Barnowski, Christopher
    Wiken, Margareta
    Willemze, Annemieke J.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2020, 42 (03) : 350 - 358
  • [45] Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports
    Wang, Michael
    Teresa Alvarez-Roman, Maria
    Chowdary, Pratima
    Quon, Doris V.
    Schafer, Kim
    BLOOD COAGULATION & FIBRINOLYSIS, 2016, 27 (07) : 737 - 744
  • [46] Comparison of fix activity of select novel recombinant fix replacement products in commonly used fda approved one-stage clot assay systems
    Robinson, M. M.
    Tiefenbacher, S.
    Ross, E. L.
    Williams, P. T.
    Cogswell, C. E.
    Wham, T. L.
    Adcock, D. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 325 - 325
  • [47] A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays
    Kitchen, S.
    Blakemore, J.
    Friedman, K. D.
    Hart, D. P.
    Ko, R. H.
    Perry, D.
    Platton, S.
    Tan-Castillo, D.
    Young, G.
    Luddington, R. J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 (04) : 757 - 764
  • [48] The activity of glycoPEGylated recombinant FVIII (N8-GP) can be measured in both two-stage chromogenic and one-stage clotting assays
    Krogh-Meibom, T.
    Olsen, E. H. N.
    Kjalke, M.
    Ezban, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 1042 - 1042
  • [49] Potency assignment and measurement of recombinant FIX activity in human plasma - impact of aPTT reagents on the 1-stage clotting assay
    Gritsch, Herbert
    Romeder-Finger, Stefan
    Scheiflinger, Friedrich
    Turecek, Peter L.
    HAEMOPHILIA, 2014, 20 : 37 - 37
  • [50] Evaluation of one-stage and chromogenic assays for the laboratory measurement of factor VIII activity following valoctocogene roxaparvovec infusion
    Platton, Sean
    Raheja, Priyanka
    Dale, Christopher
    Guy, Susan
    Yartey, Nada
    Bowyer, Annette
    HAEMOPHILIA, 2024, 30 (05) : 1221 - 1224
12345